QPPV.COM KNOWLEDGE ASSESSMENT

Durvalumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Durvalumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which operational control would most directly reduce the risk of missing delayed immune-mediated adverse reactions?

Restrict follow-up to the period between the first and final infusion Use structured delayed-event surveillance that continues after treatment discontinuation Remove treatment-stop dates from the safety database Review only events that require hospitalisation

Question 2 of 10 Why can durvalumab produce inflammatory injury in organs that are not malignant?

The antibody accumulates nonspecifically in all highly perfused organs Checkpoint blockade can permit activated immune cells to attack normal tissues The drug is metabolised into organ-specific toxic metabolites PD-L1 is expressed only in healthy organs and not in tumours

Question 3 of 10 How should the 2026 withdrawal of the proposed high-risk non-muscle-invasive bladder-cancer extension be interpreted for pharmacovigilance governance?

It demonstrates that durvalumab has been withdrawn from the EU market It invalidates the benefit-risk balance of every authorised durvalumab indication It concerns the proposed extension and does not, by itself, alter established authorised uses It proves that immune-mediated toxicity occurs only in bladder cancer

Question 4 of 10 What was the significance of the PACIFIC programme in the development history described?

It established durvalumab as an oral treatment for metastatic disease It supported checkpoint blockade after definitive chemoradiotherapy in unresectable stage III non-small-cell lung cancer It demonstrated that durvalumab should replace all platinum chemotherapy It established durvalumab only for patients with autoimmune disease

Question 5 of 10 Why can an endocrine adverse reaction be incorrectly recorded as 'recovered'?

Endocrine events are always transient and resolve without treatment Acute inflammatory symptoms may improve while permanent hormone deficiency continues to require replacement Hormone replacement proves that the original event was not immune mediated Endocrine events cannot occur after treatment discontinuation

Question 6 of 10 Which feature most strongly supports analysing an acute infusion reaction separately from delayed immune-mediated organ toxicity?

Both event types can occur only after many treatment cycles Infusion reactions are defined primarily by their temporal relationship to administration and acute symptoms Infusion reactions are always caused by tumour progression Delayed immune toxicity is limited to the infusion site

Question 7 of 10 What is the principal value of retaining the exact durvalumab product and batch when available?

It replaces the need to assess clinical causality It supports investigation of infusion or hypersensitivity events, quality complaints and potential clusters It proves that every adverse event is caused by the product It is relevant only for oral medicines

Question 8 of 10 A report describes diarrhoea during durvalumab plus chemotherapy. Which assessment best reflects the article's approach?

Code it as immune-mediated colitis based on stool frequency alone Treat it as unrelated to treatment because diarrhoea is common with chemotherapy Assess inflammatory features and alternative causes, including infection, chemotherapy, surgery and other gastrointestinal disease Exclude it unless endoscopy confirms colitis

Question 9 of 10 Which interaction is not blocked by durvalumab according to the article?

PD-L1 binding to PD-1 PD-L1 binding to CD80 PD-1 binding to PD-L2 PD-L1-mediated inhibitory signalling involving activated T cells

Question 10 of 10 Which combination of information provides the most complete reconstruction of a durvalumab case?

Adverse-event term, patient age and reporting country only Organ phenotype, indication, treatment phase, full regimen, timing, objective findings and competing causes Dose number and product batch only Tumour type and outcome without dates or concomitant treatment

Durvalumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings